Hematology-American Society of Hematology Education Program

Papers
(The H4-Index of Hematology-American Society of Hematology Education Program is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?100
The varieties of therapeutic experience: navigating treatment options for patients with PNH94
Mastocytosis demystified67
On the horizon: upcoming new agents for the management of ITP64
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?54
Bispecific antibody therapies45
Labor and delivery: DIC, HELLP, preeclampsia45
Challenges and opportunities in the long-term management of immune-mediated TTP44
Inpatient recognition and management of HLH36
Recognizing, defining, and managing CAR-T hematologic toxicities34
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment32
Anticoagulation at the end of life: whether, when, and how to treat31
Your chemo is no good here: management of high-risk MCL30
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma29
Neurological manifestations of MGUS29
Has PD-1 blockade changed the standard of care for cHL?28
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma28
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient28
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL27
Where do immunotherapies stand in management of acute leukemia in adults?27
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease27
New therapies in hemophilia: extend the half-life, mimic, or rebalance?27
Troubleshooting heparin resistance26
Optimizing outcomes in secondary AML26
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia25
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies25
0.18038582801819